Why is it hard to terminate failing projects in pharmaceutical R&D?
- PMID: 26294265
- DOI: 10.1038/nrd4725
Why is it hard to terminate failing projects in pharmaceutical R&D?
Abstract
'Quick-kill' strategies in pharmaceutical research and development aim to reduce late-stage attrition by bringing project termination decisions forward, to an earlier point in the process. How can the barriers to implementing such strategies be overcome?
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources